相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway
Minghe Lv et al.
CELL BIOLOGY AND TOXICOLOGY (2021)
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
A. Ortega-Franco et al.
ESMO OPEN (2021)
Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion
Crescenzo D'Alterio et al.
SEMINARS IN CANCER BIOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
M. Domine et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy
Susanne M. Arnold et al.
CLINICAL LUNG CANCER (2020)
The Biology of Lung Cancer Development of More Effective Methods for Prevention, Diagnosis, and Treatment
Ramin Salehi-Rad et al.
CLINICS IN CHEST MEDICINE (2020)
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
Rosalyn A. Juergens et al.
LUNG CANCER (2020)
Immunotherapeutic approaches for small-cell lung cancer
Wade T. Iams et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway
Xiao-Zhong Liao et al.
PHYTOTHERAPY RESEARCH (2020)
CircAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity
Yangling Xu et al.
BIOTECHNOLOGY LETTERS (2020)
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
Francesco Gelsomino et al.
BRITISH JOURNAL OF CANCER (2020)
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
Jiabei Zhou et al.
FRONTIERS IN PHARMACOLOGY (2020)
DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4
Janani Panneerselvam et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Lisa M. Butler et al.
ADVANCED DRUG DELIVERY REVIEWS (2020)
CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)
Yongsheng Zhao et al.
CANCER CELL INTERNATIONAL (2020)
FASN-Mediated Lipid Metabolism Regulates Goose Granulosa Cells Apoptosis and Steroidogenesis
Xi Chen et al.
FRONTIERS IN PHYSIOLOGY (2020)
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
Andreas Saltos et al.
FRONTIERS IN ONCOLOGY (2020)
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction
Yue Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription
Yunyao Liu et al.
ONCOGENE (2020)
Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway
Yiqun Liu et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2020)
FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim
Tianyu Sun et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2020)
Blocking OLFM4/HIF-1 axis alleviates hypoxia-induced invasion, epithelial-mesenchymal transition, and chemotherapy resistance in non-small-cell lung cancer
Xian-Zheng Gao et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Targeting Ferroptosis to Iron Out Cancer
Behrouz Hassannia et al.
CANCER CELL (2019)
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
Daniel Morgensztern et al.
BRITISH JOURNAL OF CANCER (2019)
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
Edo Kon et al.
DRUG RESISTANCE UPDATES (2019)
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
Todd M. Bauer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1
Hong Zhu et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago et al.
CANCER DISCOVERY (2019)
The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells
Matheus Molina Silva et al.
SCIENTIFIC REPORTS (2019)
Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer
Joshua R. Heyza et al.
CLINICAL CANCER RESEARCH (2019)
Proteasome inhibition prevents cell death induced by the chemotherapeutic agent cisplatin downstream of DNA damage
Ana Rita Costa et al.
DNA REPAIR (2019)
Cyclooxygenase-2 in cancer: A review
Nasser Hashemi Goradel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients
Jun Zhan et al.
THERANOSTICS (2019)
Aberrant lipid metabolism in cancer cells - the role of oncolipid-activated signaling
Upasana Ray et al.
FEBS JOURNAL (2018)
Lung cancer epigenetics: From knowledge to applications
Michael Duruisseaux et al.
SEMINARS IN CANCER BIOLOGY (2018)
Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins
Jin Wang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells
Mingjing Shen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2018)
Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and sternness
Jingjing Wang et al.
CANCER LETTERS (2018)
Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy
Xiao-Yan Zhang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Glutathione metabolism in cancer progression and treatment resistance
Ankita Bansal et al.
JOURNAL OF CELL BIOLOGY (2018)
Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers
Yu Han et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance
Xiang Ling et al.
NANO LETTERS (2018)
Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance
Sabrina Grasse et al.
GENOME MEDICINE (2018)
Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin
Zhao-jia Gao et al.
MEDICAL SCIENCE MONITOR (2018)
Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System
Weipeng Hong et al.
FRONTIERS IN PHARMACOLOGY (2018)
Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
Chao-Yue Sun et al.
FRONTIERS IN PHARMACOLOGY (2018)
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Muhammad Zubair Afzal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
D. E. Meyers et al.
CURRENT ONCOLOGY (2018)
FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC
Sisi Cao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy
Robert Pirker
JOURNAL OF ONCOLOGY PRACTICE (2018)
Emerging Cellular Therapies for Cancer
Sonia Guedan et al.
Annual Review of Immunology (2018)
FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells
Yuwen He et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation
Qiang Zhang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2018)
Ganetespib for small cell lung cancer
Deepa S. Subramaniam et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets
Si Sun et al.
ONCOTARGET (2017)
Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression
Terumasa Sowa et al.
CANCER MEDICINE (2017)
Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells
Mia C. Akerfeldt et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer
Shucai Yang et al.
MOLECULAR CANCER (2017)
FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer (vol 11, pg 640, 2017)
Lingfeng He et al.
MOLECULAR ONCOLOGY (2017)
MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
Irina Fadejeva et al.
ONCOTARGET (2017)
Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells
Maria Elena Pisanu et al.
CANCER LETTERS (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
Lipid metabolism and lung cancer
Maria Merino Salvador et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage
Wai-Kin Yu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Platinum-based drugs: past, present and future
Shahana Dilruba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells
Muhammad Baghdadi et al.
CANCER RESEARCH (2016)
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
D. A. Fennell et al.
CANCER TREATMENT REVIEWS (2016)
Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation
Jose Alexandre Ferreira et al.
DRUG RESISTANCE UPDATES (2016)
Histological grading in lung cancer: one system for all or separate systems for each histological type?
William D. Travis et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression
Cen Zhang et al.
GENES & DEVELOPMENT (2016)
Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Gema Santamaria Nunez et al.
MOLECULAR CANCER THERAPEUTICS (2016)
ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells
Shaomin Shi et al.
ONCOLOGY REPORTS (2016)
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Claudio Vernieri et al.
CANCER DISCOVERY (2016)
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer A Review
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy
Lucas B. Sullivan et al.
NATURE REVIEWS CANCER (2016)
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Nissim Hay
NATURE REVIEWS CANCER (2016)
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
Veronique Dieras et al.
ONCOLOGY AND THERAPY (2016)
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
P. Mitchell et al.
ANNALS OF ONCOLOGY (2015)
Phase I/II study of gefitinib (Iressa(A (R))) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
Ji-Youn Han et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis
Giulia Bertolini et al.
CANCER RESEARCH (2015)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng et al.
CANCER TREATMENT REVIEWS (2015)
RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance
Daphna Mokady et al.
DRUG RESISTANCE UPDATES (2015)
Broad targeting of resistance to apoptosis in cancer
Ramzi M. Mohammad et al.
SEMINARS IN CANCER BIOLOGY (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules
Shanzhou Duan et al.
ONCOTARGET (2015)
Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance
Jesus Garcia-Cano et al.
ONCOTARGET (2015)
A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer
Saiama N. Waqar et al.
CHEMOTHERAPY (2015)
Dicarbonyl proteome and genome damage in metabolic and vascular disease
Naila Rabbani et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
L-H Wang et al.
BRITISH JOURNAL OF CANCER (2014)
SIRT1 and AMPK Mediate Hypoxia-Induced Resistance of Non-Small Cell Lung Cancers to Cisplatin and Doxorubicin
Dong Hoon Shin et al.
CANCER RESEARCH (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
The pentose phosphate pathway and cancer
Krushna C. Patra et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells
Wei Qian et al.
ONCOTARGET (2014)
A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
J. M. Sun et al.
BRITISH JOURNAL OF CANCER (2013)
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Wynand P. Roos et al.
CANCER LETTERS (2013)
Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non-Small Cell Lung Cancer Cells
Hirohito Yamaguchi et al.
CLINICAL CANCER RESEARCH (2013)
TIM-4 Glycoprotein-Mediated Degradation of Dying Tumor Cells by Autophagy Leads to Reduced Antigen Presentation and Increased Immune Tolerance
Muhammad Baghdadi et al.
IMMUNITY (2013)
nab-Paclitaxel mechanisms of action and delivery
Denise A. Yardley
JOURNAL OF CONTROLLED RELEASE (2013)
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer
Francesca Mazzoni et al.
LUNG CANCER (2013)
Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
Martin P. Barr et al.
PLOS ONE (2013)
Autophagy: shaping the tumor microenvironment and therapeutic response
Hannelore Maes et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Cancer immunotherapy: accomplishments to date and future promise
Karim Y. Helmy et al.
THERAPEUTIC DELIVERY (2013)
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy
M. Bartucci et al.
CELL DEATH AND DIFFERENTIATION (2012)
Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients
Xiaojing Xu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
Zhuang-hua Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy
Helen H. W. Chen et al.
LUNG CANCER (2012)
Valproic acid overcomes hypoxia-induced resistance to apoptosis
Simon Cipro et al.
ONCOLOGY REPORTS (2012)
Chemoresistance of Lung Cancer Stemlike Cells Depends on Activation of Hsp27
Han-Shui Hsu et al.
CANCER (2011)
Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
Christoph Wohlkoenig et al.
CANCER LETTERS (2011)
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target
Wenshu Chen et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
CANCER Macrophages limit chemotherapy
Michele De Palma et al.
NATURE (2011)
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer
Elaine T. Lam et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling
James P. Sullivan et al.
CANCER RESEARCH (2010)
Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group
Shadia Jalal et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
N. Mylonakis et al.
LUNG CANCER (2010)
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
G. L. Semenza
ONCOGENE (2010)
Lipoplatin ™ Monotherapy: A Phase II Trial of Second-Line Treatment of Metastatic Non-Small-Cell Lung Cancer
A. Ravaioli et al.
JOURNAL OF CHEMOTHERAPY (2009)
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction
Hecheng Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
Francesca Russo et al.
BMC CANCER (2008)
The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer
Sumanta Kumar Pal et al.
CLINICAL LUNG CANCER (2008)
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
Khoi Q. Tran et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Gefitinib plus celecoxilb in chernotherapy-naive patients with stage IIIB/IV non-small cell lung cancer - A phase II study from the Hoosier Oncology Group
Anuj Agarwala et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin
Hak-Ryul Kim et al.
LUNG CANCER (2008)
The roles of copper transporters in cisplatin resistance
Macus Tien Kuo et al.
CANCER AND METASTASIS REVIEWS (2007)
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel et al.
CANCER AND METASTASIS REVIEWS (2007)
Platinum transporters and drug resistance
Min-Koo Choi et al.
ARCHIVES OF PHARMACAL RESEARCH (2006)
Multidrug resistance, in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease
Nadja Triller et al.
LUNG CANCER (2006)
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
Michael P. Fanucchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
TLK-286:: a novel glutathione S-transferase-activated prodrug
KD Tew
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines
David A. Weaver et al.
MOLECULAR CANCER (2005)
Cellular processing of platinum anticancer drugs
D Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
S Ishida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
